KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price

Shares of Kyverna Therapeutics (KYTX) fell on Thursday even after the company reported that a one-time cell therapy kept helping patients with stiff person syndrome (SPS) and generalized myasthenia gravis a full year later.Investors had already priced in much of the good news after earlier trial re…